HELP Helus Pharma Inc. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1833141 · Reporting currency CAD · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2025*2025-03-31 | FY2024*2024-03-31 | FY2023*2023-03-31 | FY2022*2022-03-31 | FY2021*2021-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | 0 | 864,000 |
| Cost of revenue | — | — | — | 0 | 664,000 |
| Gross profit | — | — | — | 0 | 200,000 |
| R&D expense | 54.91M | 32.36M | 25.49M | 17.59M | 3.30M |
| SG&A expense | 45.37M | 32.59M | 21.34M | 28.22M | 15.87M |
| Income tax | 0 | 0 | 0 | 0 | 0 |
| Net income | -113.14M | -78.08M | -47.49M | -67.63M | -32.22M |
| EPS (basic) | -5.59 | -9.41 | -0.26 | -0.40 | -0.32 |
| EPS (diluted) | — | — | -0.26 | -0.40 | -0.32 |
| Balance sheet | |||||
| Cash & equivalents | 135.02M | 208.99M | 16.63M | 53.64M | 64.03M |
| Receivables | 5.88M | 4.48M | 3.05M | 2.10M | 1.33M |
| Current assets | 165.97M | 218.54M | 23.18M | 58.35M | 66.48M |
| PP&E, netmay include right-of-use assets (IFRS) | 141,000 | 266,000 | 450,000 | 491,000 | 557,000 |
| Goodwill | 51.49M | 47.48M | 24.79M | 22.89M | 23.37M |
| Intangibles | 41.02M | 35.47M | 5.47M | 2.08M | 1.70M |
| Total assets | 258.62M | 302.02M | 53.90M | 84.06M | 92.11M |
| Current liabilities | 21.42M | 10.10M | 5.66M | 7.91M | 4.90M |
| Total liabilities | 21.42M | 10.10M | 5.66M | 7.91M | 5.99M |
| Shareholders' equity | 237.20M | 291.93M | 48.23M | 76.16M | 86.12M |
| Cash flow statement | |||||
| Operating cash flow | -101.30M | -68.91M | -47.43M | -45.21M | -19.03M |
| Capital expenditure | — | 21,000 | 142,000 | 105,000 | 135,000 |
| Free cash flow | — | -68.93M | -47.57M | -45.31M | -19.16M |
| Investing cash flow | -1.97M | 6.92M | -3.31M | -770,000 | -1.19M |
| Financing cash flow | 20.20M | 254.51M | 13.56M | 35.78M | 82.72M |
| Depreciation & amortization | 475,000 | 424,000 | 251,000 | — | — |
| Stock-based compensation | 42.87M | 13.89M | 4.69M | 18.03M | 11.55M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.